The stock has remained subdued over the last few weeks, but the last couple of trading sessions have led to some appreciation. The volumes on Friday were very high compared to the recent averages, and the stock appreciated by 4%. There was no official release on the company website which could have prompted the surge in volumes. The next week may be important to see how the momentum plays out. The results for Q2'13 had shown decline in net loss from $4 million to $1 million, while the revenues remained flat. For the first half of 2013, the sales increased by 13% to $5 million compared to $4.455 million in H1'12. It reported a net profit of $479K in H1'13 compared to a net loss of $8.4 million in H1'12. This was due to the $2.9 million received on sale of BluScience to NeutriSci. Even if this inflow is excluded, there was a remarkable drop in the net loss. The gross profit in H1'13 was $1.633 million compared to $160K H1'12, which is again a huge rise. The company received 200K in July from NeutriSci, and expects to receive additional $883K from it before December 2013. Deal with Thorne Research is expected to help the company increase inflows going forward. The deal is worth $3.5 million, and the company will also receive royalties in addition to this. As per the management, more products containing NR are expected to be launched over the next few quarters. HPN had recently launched its product containing NR to support neuroprotection in contact sports. In addition, the Company recently licensed from Green Molecular S.L. exclusive worldwide patent rights related to the use of pterostilbene for the prevention / treatment of skin diseases.